| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1038/NRCLINONC.2010.87 |
| P698 | PubMed publication ID | 20551943 |
| P50 | author | Guillermo Garcia-Manero | Q66385413 |
| P2093 | author name string | Alfonso Quintás-Cardama | |
| Fabio P S Santos | |||
| P2860 | cites work | Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex | Q24324026 |
| Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study | Q24563021 | ||
| Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor | Q28217975 | ||
| DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia | Q83364381 | ||
| Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study | Q28301602 | ||
| International scoring system for evaluating prognosis in myelodysplastic syndromes | Q28305247 | ||
| A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines | Q28472733 | ||
| Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer | Q29615066 | ||
| DNA methylation and human disease | Q29615417 | ||
| Gene silencing in cancer in association with promoter hypermethylation | Q29617274 | ||
| Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes | Q33366330 | ||
| DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes | Q33628772 | ||
| Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes | Q33813750 | ||
| Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia | Q33861150 | ||
| Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients | Q33891633 | ||
| Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia | Q33899678 | ||
| Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine | Q34088756 | ||
| Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. | Q34128471 | ||
| Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. | Q34204305 | ||
| Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia | Q34553286 | ||
| Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. | Q34559054 | ||
| Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia | Q34615081 | ||
| Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia | Q34615087 | ||
| Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia | Q34659942 | ||
| 5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. | Q34721445 | ||
| Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. | Q34772133 | ||
| Dissecting oncogenes and tyrosine kinases in AML cells. | Q35576845 | ||
| Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia | Q35848726 | ||
| Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation | Q35939534 | ||
| A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy | Q35968482 | ||
| Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid | Q36001895 | ||
| Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial | Q36934269 | ||
| Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines | Q37066258 | ||
| Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. | Q37086937 | ||
| RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma | Q37268965 | ||
| Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment | Q37372798 | ||
| Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. | Q37372837 | ||
| MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation | Q37396081 | ||
| Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities | Q37480178 | ||
| An ATM- and Rad3-related (ATR) signaling pathway and a phosphorylation-acetylation cascade are involved in activation of p53/p21Waf1/Cip1 in response to 5-aza-2'-deoxycytidine treatment | Q38296791 | ||
| 5-Azacytidine—A New Anticancer Drug with Significant Activity in Acute Myeloblastic Leukemia | Q39447697 | ||
| The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells | Q39887368 | ||
| A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts | Q39959137 | ||
| DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. | Q40054309 | ||
| Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation | Q40198158 | ||
| Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk. | Q40218154 | ||
| Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid | Q40415058 | ||
| DNA methylation changes in hematologic malignancies: biologic and clinical implications | Q41455032 | ||
| Cellular differentiation, cytidine analogs and DNA methylation | Q42242732 | ||
| Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine | Q43105406 | ||
| Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study | Q43993868 | ||
| Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment | Q44155422 | ||
| Characteristics of mouse leukemic cells resistant to 5-azacytidine and 5-aza-2'-deoxycytidine. | Q44309990 | ||
| Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients | Q44347691 | ||
| Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies | Q44646952 | ||
| 5-AZA-2′-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation | Q45117672 | ||
| Myelodysplastic syndromes--coping with ineffective hematopoiesis | Q45259429 | ||
| Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. | Q45917429 | ||
| Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes | Q46102907 | ||
| Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial | Q46236663 | ||
| Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia | Q46416418 | ||
| Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). | Q46727255 | ||
| Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation fo | Q48693524 | ||
| Biochemical mechanisms of drug resistance IV. Development of resistance to 5-azacytidine and simultaneous depression of pyrimidine metabolism in leukemic mice | Q54698572 | ||
| Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia | Q68983990 | ||
| The mechanism of inhibition of protein synthesis by 5-azacytidine in HeLa cells | Q70004129 | ||
| Kinetic studies on phosphorylation of 5-azacytidine with the purified uridine-cytidine kinase from calf thymus | Q70023824 | ||
| Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia | Q71611069 | ||
| Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes | Q72078678 | ||
| Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: A southwest oncology group study | Q72633548 | ||
| Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine | Q72656874 | ||
| Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia | Q72657219 | ||
| Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60) | Q72683682 | ||
| Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2'-deoxycytidine as a possible mechanism of chemotherapeutic action | Q72700799 | ||
| Kinetic interaction of 5-AZA-2'-deoxycytidine-5'-monophosphate and its 5'-triphosphate with deoxycytidylate deaminase | Q72734035 | ||
| 5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias | Q72745228 | ||
| 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia | Q72992294 | ||
| Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome | Q73296079 | ||
| Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression | Q74412911 | ||
| Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia | Q78125085 | ||
| Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms | Q79734535 | ||
| Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome | Q80538299 | ||
| CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine | Q80568676 | ||
| Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7 | Q80651795 | ||
| New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients | Q80860421 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 433-444 | |
| P577 | publication date | 2010-06-15 | |
| P1433 | published in | Nature Reviews Clinical Oncology | Q641640 |
| P1476 | title | Therapy with azanucleosides for myelodysplastic syndromes | |
| P478 | volume | 7 |
| Q35423470 | 5-aza-2'-deoxycytidine activates iron uptake and heme biosynthesis by increasing c-Myc nuclear localization and binding to the E-boxes of transferrin receptor 1 (TfR1) and ferrochelatase (Fech) genes. |
| Q39395000 | 5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity. |
| Q35130668 | A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine |
| Q34204750 | A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia |
| Q58088037 | Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target |
| Q41488932 | Chromatin remodeling--a novel strategy to control excessive alcohol drinking |
| Q39317758 | Chromatin remodeling: a new landscape to treat harmful alcohol-use disorders. |
| Q33407030 | Decitabine: a review of its use in older patients with acute myeloid leukaemia |
| Q37192391 | Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. |
| Q35835175 | Epigenetic activities of flavonoids in the prevention and treatment of cancer |
| Q38298238 | Epigenetic control of myeloid cell differentiation, identity and function. |
| Q38330746 | Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment |
| Q36166026 | Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2'-deoxycytidine |
| Q38770916 | Epigenetics: A primer for clinicians |
| Q36290974 | Five-aza-2'-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells |
| Q82463891 | Grand Challenge Commentary: The chemistry of a dynamic genome |
| Q35553330 | HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL |
| Q90332140 | Inhibition of DNA Methylation at the MLH1 Promoter Region Using Pyrrole-Imidazole Polyamide |
| Q37169118 | Inhibition of DNA Methyltransferases Blocks Mutant Huntingtin-Induced Neurotoxicity |
| Q38762107 | Lack of cross-resistance to FF-10501, an inhibitor of inosine-5'-monophosphate dehydrogenase, in azacitidine-resistant cell lines selected from SKM-1 and MOLM-13 leukemia cell lines |
| Q36158234 | Lack of mutational hot spots during decitabine-mediated HIV-1 mutagenesis |
| Q34025097 | Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors. |
| Q36070627 | Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humans |
| Q34769855 | Promoter DNA methylation pattern identifies prognostic subgroups in childhood T-cell acute lymphoblastic leukemia |
| Q38962596 | Quantitative determination of decitabine incorporation into DNA and its effect on mutation rates in human cancer cells |
| Q38920820 | Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest |
| Q64951123 | Synthesis of azanucleosides through regioselective ring-opening of epoxides catalyzed by sulphated zirconia under microwave and solvent-free conditions. |
| Q33715010 | TET enzymes, TDG and the dynamics of DNA demethylation. |
| Q38755884 | Targeted TET oxidase activity through methyl-CpG-binding domain extensively suppresses cancer cell proliferation. |
| Q53201323 | Targeting the epigenome for treatment of cancer. |
| Q41664988 | The combination of dimethoxycurcumin with DNA methylation inhibitor enhances gene re-expression of promoter-methylated genes and antagonizes their cytotoxic effect |
Search more.